- Home
- CET vs OGN Comparison
CET vs OGN Comparison
Compare CET & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CET | OGN |
|---|---|---|
| Founded | 1929 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CET | OGN |
|---|---|---|
| Price | $51.63 | $7.70 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | 52.0K | ★ 6.1M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 5.22% | 1.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.40 | 1.91 |
| Revenue | $27,062,484.00 | ★ $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.99 | ★ $4.09 |
| Revenue Growth | ★ 15.78 | N/A |
| 52 Week Low | $40.24 | $6.18 |
| 52 Week High | $52.95 | $17.23 |
Technical Indicators
Market Signals| Indicator | CET | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 39.51 |
| Support Level | $51.35 | $7.74 |
| Resistance Level | $52.62 | $8.48 |
| Average True Range (ATR) | 0.75 | 0.39 |
| MACD | -0.10 | -0.17 |
| Stochastic Oscillator | 17.50 | 3.70 |
Price Performance
Historical ComparisonAbout CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.